First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

Zelenectide pevedotin monotherapy demonstrated a generally well-tolerated safety profile and preliminary efficacy, particularly in UC, supporting investigation of UC and non-UC populations in the expansion phase.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-11-06
DOI
https://doi.org/10.1200/jco-25-00559
Citations
2
Primary Topic
Cancer therapeutics and mechanisms
Type
article
Field-Weighted Citation Impact
1.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

Meredith McKean, Elisa Fontana, Rajiv Sharma, Amy L. Dickson et al.
2 citations
Journal of Clinical Oncology
Cancer therapeutics and mechanisms
1.61
article

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

Meredith McKean, Elisa Fontana, Rajiv Sharma, Amy L. Dickson, Júlia Lostes, Òscar Reig, Capucine Baldini, Bernard Doger de Spéville, Jordi Rodón, Carly Campbell, Louise Carter, Vincent Goldschmidt, Jason Robert Brown, Antoîne Italiano, Justin Bader, Gerald S. Falchook, Loïc Verlingue, Kate Josephs, Leslie R. DeMars, Andrea Necchi, Cong Xu, Sophie Cousin
article en
2 citations

Abstract

Zelenectide pevedotin monotherapy demonstrated a generally well-tolerated safety profile and preliminary efficacy, particularly in UC, supporting investigation of UC and non-UC populations in the expansion phase.

Journal of Clinical OncologyVol. 43(35)
The University of Texas MD Anderson Cancer Center (US), Université de Bordeaux (FR), Vita-Salute San Raffaele University (IT), Sarah Cannon Research Institute (GB), Breast Cancer Research Foundation (US), Institut Gustave Roussy (FR), University of Manchester (GB), Sarah Cannon (US), Centre Léon Bérard (FR), University Hospitals Seidman Cancer Center (US), HealthONE (US), Vall d'Hebron Hospital Universitari (ES), Hospital Universitario Fundación Jiménez Díaz (ES), IRCCS Ospedale San Raffaele (IT), The Christie NHS Foundation Trust (GB), Institut Bergonié (FR), Bicycle Therapeutics (United Kingdom) (GB), Vall d'Hebron Institute of Oncology (ES), Case Western Reserve University (US)
Openalex Percentile: Top 14%
Cancer therapeutics and mechanisms
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.